17607 Gold Plaza, Omaha, NE
402-991-8468
Patient Portal
Menu

News

ENDOCYTE ANNOUNCES ENROLLMENT OF FIRST PATIENT IN PHASE 3 VISION TRIAL OF 177LU-PSMA-617 IN PROSTATE CANCER

June 8, 2018

Endocyte, Inc. (Nasdaq:ECYT) announced the enrollment of the first patient in its global phase 3 VISION trial of 177Lu-PSMA-617 in prostate cancer by Dr. Luke Nordquist at Urology Cancer Center in Omaha, NE, a member of Precision Cancer Research.

View Article

The Real-Life Patient Impact of Pharmacy Benefit Managers

January 10, 2018

There is growing awareness of the problems and pitfalls with Pharmacy Benefit Managers (PBMs)
in the United States health care system. Contracted by insurance carriers to negotiate on their
behalf with pharmaceutical companies, these ‘middle men’ corporations have quietly become an
unavoidable part of our nation’s health care system.

Download Article

Apalutamide Granted FDA’s Priority Review for Nonmetastatic CRPC

December 26, 2017

Based on data from the phase III SPARTAN trial (ARN-509-003), apalutamide (ARN-509) has been granted a priority review by the FDA for the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC), according to Janssen Biotech, the manufacturer of the next-generation oral androgen receptor inhibitor.

View Article

J&J announces positive data from the SPARTAN trial of apalutamide (ARN-509)

October 13, 2017

Janssen Biotech has submitted a New Drug Application to the US Food & Drug Administration for the approval of apalutamide (formerly ARN-509) in the treatment of non-metastatic, castration-resistant prostate cancer (nmCRPC).

View Article

First-Line Immunotherapy for Cisplatin-Ineligible Patients With Advanced Urothelial Cancer

October 13, 2017

first-line pembrolizumab (Keytruda) produced durable responses in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer in the phase II KEYNOTE-052 trial.

View Article